Navigation Links
Survival Benefit With Syndax Pharmaceuticals' Entinostat Maintained in Women with Advanced Breast Cancer
Date:12/7/2011

mestane + placebo HR = 0.58 (95%CI: 0.34, 0.97) p = 0.04
  • Progression-free survival: 4.3 months for exemestane + entinostat vs. 2.3 months for exemestane + placebo HR = 0.73 (95%CI: 0.49, 1.09) p = 0.06; 1-sided significance prospectively defined as  <0.10
  • Progression-free survival of 8.5 months for exemestane + entinostat in subset of patients with increased protein acetylaton vs. 2.8 months in non acetylators HR = 0.32 (95%CI: 0.13, 0.79)
  • Trend in improved progression-free survival in hormone-resistant vs. hormone-sensitive patients
  • Exemestane combined with entinostat was well tolerated with the most frequent adverse events consisting of fatigue, gastrointestinal disturbances and hematologic abnormalities
  • "The continued survival benefit increases our confidence that entinostat will play a critical role in the treatment of women with estrogen receptor-positive metastatic breast cancer," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "We look forward to moving entinostat into phase 3 clinical testing in 2012."

    San Antonio Breast Cancer Symposium
    Presentation Date/Time: Wednesday, December 7 from 5:00 PM - 7:00 PM
    Poster Title: Entinostat, a Novel Histone Deacetylase Inhibitor, Added to Exemestane Improves PFS in Advanced Breast Cancer in a Randomized, Phase II, Double-Blind Study
    Session: POSTER DISCUSSION I: Endocrine Resistance
    Abstract Number: PD01-04
    Location: Ballroom A

    Breast Cancer and Hormone Therapy
    Approximately 230,000 new cases of invasive breast cancer are diagnosed in women annually in the United States and there are approximately 150,000 women living with metastatic breast cancer (MBC).  Over 70 percent of women with breast cancer have estrogen receptor-positive (ER+) breast cancer.  The most effective cancer treatments target the underlying biology and in breast canc
    '/>"/>

    SOURCE Syndax Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
    2. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
    3. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
    4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
    5. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
    6. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    7. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
    8. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
    9. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
    10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
    11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... Feb. 27, 2015 Roughly three-quarters of ... confident substituting an interchangeable biosimilar for its branded ... same nonproprietary name, according to a survey published ... Journal of Managed Care & Specialty Pharmacy ... percent of pharmacists would feel as confident if ...
    (Date:2/27/2015)... Feb. 27, 2015 The role of the ... but one thing hasn,t changed: face-to-face meetings are seen ... with Key Opinion Leaders. Yet at the ... valuable type of interaction, field medical teams within the ... interactions. This is just one of the challenges addressed ...
    (Date:2/27/2015)... NEW YORK , Feb. 27, 2015  Pomerantz ... Vitae Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com ... whether Vitae and certain of its officers and/or directors ... Exchange Act of 1934.  On February ...
    Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2
    ... and LYNBROOK, N.Y., Aug. 31, 2011 Auxilium Pharmaceuticals, ... company, and BioSpecifics Technologies Corp. (NASDAQ: BSTC ... dismissed all pending litigation between the Companies and announced ... cellulite and human and canine lipoma as well as ...
    ... 31, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... Torley, M.B. Ch. B., M.R.C.P.,  as Executive Vice President ... will report to N. Anthony Coles, M.D., President and ... commercial activities related to Nexavar and the potential launch ...
    Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3
    (Date:3/1/2015)... 01, 2015 “ The Barrel Mill ” ... Report, which takes a look at the latest and coolest ... host of NewsWatch and a technology expert, conducted the review ... flavor to drinks. , According to Home Distillation of Alcohol, ... spirits. Well, there’s a pretty cool product that’ll help anyone ...
    (Date:2/28/2015)... 2015 Heart diseases are on the ... of urban adult population and 5 percent of rural ... and 20-30 percent of them require specialized investigation and ... coronary vascular diseases (CVD). , A division of Indian ... research report titled “Indian Coronary Stent Market Forecast to ...
    (Date:2/28/2015)... The Classic Denture Center , located ... Throughout all of March patients can receive $25 ... service can help overall mouth health and give ... notice certain symptoms that suggest the denture teeth are ... , 1.    Pain, clicking, and popping in the joints, 2.    Pain ...
    (Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
    (Date:2/28/2015)... February 28, 2015 Dr. Perry ... Coast area residents, recently announced a special offer for ... a treatment option for new and established patients at ... with a bright, white smile, Dr. Patel and his ... $299, marked down from the regular price of $450. ...
    Breaking Medicine News(10 mins):Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
    ... world’s first genetically altered chicken eggs that can be used to ... of the Roslin Institute at Edinburgh, Scotland have claimed ... that can be used to create life saving drugs. ... fraction of what the National Health Service incurs, according to them. ...
    ... a source of bone for grafting may avoid the complications ... according to a report in the November/December issue //of The ... bone could become the new standard for harvesting bone grafts ... Polley and colleagues of Rush University Medical Center, Chicago. ...
    ... have announced the discovery of another gene responsible for ... of the disease (occurring in around 90 percent of ... from Boston University, the University of Toronto, and Columbia ... published in Nature Genetics. ,The reasearchers ...
    ... bigger trial of a vaccine against the most common form ... time for many. // ,The vaccine called Stimuvax was ... to conventional treatment and suggested that the vaccine might be ... the online edition of BBC News. ,The vaccine ...
    ... by scientists at the Vanderbilt Kennedy Center for Research ... prenatal exposure to cocaine and behavioral //and neurological problems ... the Journal of Neuroscience, Gregg Stanwood, Ph.D., and Pat ... exposure to cocaine in rabbits, which caused a prolonged ...
    ... Minnesota Medical School, have found that - families whose meals ... unhealthy eating habits, //poor access to healthy foods at home, ... were published in the January 2007 issue of Public Health ... environment of families who ate fast food for dinner more ...
    Cached Medicine News:Health News:No Pills Just Omelets 2Health News:New Technique Uses Pubic Bone for Grafting 2Health News:New Gene to Help in Understanding Alzheimer’s Diseas 2Health News:Cocaine During Pregnancy can Cause Behavioral and Neurological Problems in the Child 2Health News:Cocaine During Pregnancy can Cause Behavioral and Neurological Problems in the Child 3Health News:Fast Food Limits Healthy Food Intake, Increases Obesity Risk 2
    9 inch double ended with one end black and the other end with 49 holes...
    49 pinholes, black...
    Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
    Long handle occluders are approximately 9 inches long....
    Medicine Products: